In Search of the Molecular Mechanisms Mediating the Inhibitory Effect of the GnRH Antagonist Degarelix on Human Prostate Cell Growth
Fig 7
Caspase 3/7 activation levels showing apoptosis of the prostate cell lines after treatment with the GnRH antagonist, degarelix.
(A) WPE1-NA22, (B) BPH-1, (C) LNCaP, and (D) VCaP. The data are expressed in terms of the percentage of the respective control and the average ± standard error. Each assay was done in triplicate with at least n = 3 independent experiments for each cell line. Two-way ANOVA indicated that there was a significant difference overall for degarelix treatment (p<0.001 for WPE1-NA22 and BPH-1; p<0.05 for VCaP), and the posttest indicated that there were differences against each control, as displayed in each graph (*p<0.05 and ***p<0.001).